NASDAQ:ARQT
Arcutis Biotherapeutics Inc Stock News
$9.20
+0.0800 (+0.88%)
At Close: May 17, 2024
WESTLAKE VILLAGE, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments
Presentations will highlight new data on the safety, efficacy, and tolerability of once-daily, topical roflumilast cream for the treatment of chronic, mild-to-severe plaque psoriasis as well as once-d
Poster presentations highlight new data for roflumilast cream, including long-term safety and efficacy results in adults with chronic plaque psoriasis Poster presentations highlight new data for roflu
Arcutis to Present at the Cowen 41st Annual Health Care Conference
05:15pm, Thursday, 25'th Feb 2021
WESTLAKE VILLAGE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo
Arcutis Biotherapeutics, Inc. (ARQT) Upgraded to Buy: Here's Why
12:52pm, Wednesday, 03'rd Feb 2021
Arcutis Biotherapeutics, Inc. (ARQT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock
08:03pm, Tuesday, 02'nd Feb 2021
WESTLAKE VILLAGE, Calif,, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializi
Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock
04:09pm, Monday, 01'st Feb 2021
WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializi
ARQT Stock Price Increases Over 25%: Why It Happened
02:34pm, Monday, 01'st Feb 2021
The stock price of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is trading at over 25% today. This is why it happened.
WESTLAKE VILLAGE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediat
WESTLAKE VILLAGE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediat
Matthew Moore Joins Arcutis as Chief Business Officer
09:00am, Monday, 11'th Jan 2021
WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo
Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index
09:27am, Monday, 21'st Dec 2020
WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo
Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020
09:00am, Wednesday, 09'th Dec 2020
WESTLAKE VILLAGE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo
WESTLAKE VILLAGE, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments f
Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020
04:05pm, Wednesday, 02'nd Dec 2020
WESTLAKE VILLAGE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments fo
